Literature DB >> 34076720

Nailfold capillaroscopy changes associated with anti-RNP antibodies in systemic lupus erythematosus.

Pramod Prahlad Chebbi1,2, Ruchika Goel3, J Ramya1,4, M Gowri5, ArianeL Herrick6, Debashish Danda1.   

Abstract

Anti-U1RNP antibody is associated with distinct organ involvement in patients with systemic lupus erythematosus (SLE). Nailfold capillaroscopy (NFC) allows non-invasive assessment of microvascular abnormalities in several connective tissue diseases. The objective of this study is to determine the association of anti-U1RNP antibody with microvascular changes by NFC in RNP-positive SLE patients in comparison with RNP-negative SLE patients (negative disease controls) and mixed connective tissue disease (MCTD) cases (positive disease controls). NFC examination was performed in consecutive patients with SLE with or without anti-U1RNP positivity. MCTD patients were recruited as disease controls. Abnormalities noted in the three groups were compared using non-parametric tests. Ordinal logistic or linear regression was used wherever applicable. 81 patients were studied, of whom 28 were diagnosed as RNP-positive SLE (age 30.0 ± 10.37; 26 females), 26 were RNP-negative SLE (age 29.42 ± 9.20; 25 females) and 27 had MCTD (age36.5 ± 9.70; 25 females). RNP-positive SLE patients had more frequent giant capillaries, enlarged capillaries and ramified capillaries as compared to RNP-negative SLE (p = 0.05, < 0.01 and 0.03, respectively). The capillary density was lower in patients with MCTD as compared with patients with RNP-positive SLE (5.11 ± 1.69/mm vs 7.25 ± 1.38/ mm, p < 0.01) and RNP-negative SLE (8.92 ± 1.13/mm, p < 0.01). The reduction in capillary density was less severe in patients with RNP-negative SLE as compared with RNP-positive SLE (OR = 0.1058 [95% CI = 0.02-0.546], p < 0.01) which was independent of the presence of Raynaud's phenomenon, interstitial lung disease and disease duration. Presence of anti-U1RNP antibody is associated with notable patterns of microvascular abnormalities in SLE. These NFC abnormalities are noted more profoundly in patients with MCTD and are less marked in RNP-negative SLE patients.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  MCTD; Nailfold capillaroscopy; RNP antibody; SLE; Videocapillaroscopy

Mesh:

Year:  2021        PMID: 34076720     DOI: 10.1007/s00296-021-04894-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  22 in total

1.  Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests.

Authors:  Elizabeth Benito-Garcia; Peter H Schur; Robert Lahita
Journal:  Arthritis Rheum       Date:  2004-12-15

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis.

Authors:  M Cutolo; A Sulli; C Pizzorni; S Accardo
Journal:  J Rheumatol       Date:  2000-01       Impact factor: 4.666

4.  Patterns of finger capillary abnormalities in connective tissue disease by "wide-field" microscopy.

Authors:  H R Maricq; E C LeRoy
Journal:  Arthritis Rheum       Date:  1973 Sep-Oct

5.  Intra-and inter-observer reliability of nailfold videocapillaroscopy - A possible outcome measure for systemic sclerosis-related microangiopathy.

Authors:  Graham Dinsdale; Tonia Moore; Neil O'Leary; Philip Tresadern; Michael Berks; Christopher Roberts; Joanne Manning; John Allen; Marina Anderson; Maurizio Cutolo; Roger Hesselstrand; Kevin Howell; Carmen Pizzorni; Vanessa Smith; Alberto Sulli; Marie Wildt; Christopher Taylor; Andrea Murray; Ariane L Herrick
Journal:  Microvasc Res       Date:  2017-02-02       Impact factor: 3.514

6.  Nail fold capillaroscopy: normal findings in children and adolescents.

Authors:  M T Terreri; L E Andrade; M L Puccinelli; M O Hilário; J Goldenberg
Journal:  Semin Arthritis Rheum       Date:  1999-08       Impact factor: 5.532

7.  Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients.

Authors:  D Alarcón-Segovia; M H Cardiel
Journal:  J Rheumatol       Date:  1989-03       Impact factor: 4.666

8.  Feasibility of different capillaroscopic measures for identifying nailfold microvascular alterations.

Authors:  Francesca Ingegnoli; Roberta Gualtierotti; Chiara Lubatti; Lenka Zahalkova; Laura Meani; Patrizia Boracchi; Silvana Zeni; Flavio Fantini
Journal:  Semin Arthritis Rheum       Date:  2007-12-31       Impact factor: 5.532

9.  Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients.

Authors:  A Sulli; M E Secchi; C Pizzorni; M Cutolo
Journal:  Ann Rheum Dis       Date:  2007-11-23       Impact factor: 19.103

10.  Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus.

Authors:  I E A Hoffman; I Peene; L Meheus; T W J Huizinga; L Cebecauer; D Isenberg; K De Bosschere; F Hulstaert; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

View more
  2 in total

1.  The diagnostic challenge of patients with anti-U1-RNP antibodies.

Authors:  Ines Elhani; Kathy Khoy; Delphine Mariotte; Elisabeth Comby; Christian Marcelli; Brigitte Le Mauff; Alexandra Audemard-Verger; Jonathan Boutemy; Gwénola Maigné; Nicolas Martin Silva; Achille Aouba; Hubert de Boysson
Journal:  Rheumatol Int       Date:  2022-07-27       Impact factor: 3.580

2.  Microvascular capillaroscopic abnormalities and occurrence of antinuclear autoantibodies in patients with sarcoidosis.

Authors:  Francesco Cattelan; Elvis Hysa; Emanuele Gotelli; Carmen Pizzorni; Pietro Francesco Bica; Marco Grosso; Emanuela Barisione; Sabrina Paolino; Luca Carmisciano; Alberto Sulli; Vanessa Smith; Maurizio Cutolo
Journal:  Rheumatol Int       Date:  2022-08-30       Impact factor: 3.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.